SPC441
Mirikisúmab
Status:
VeittApplication date:
2.10.2023Application published:
15.11.2024Grant published:
15.7.2025
Max expiry date:
29.5.2038Medicine name:
OmvohMedicine for children:
No
Timeline
Today
2.10.2023Application
15.11.2024Publication
15.7.2025Registration
29.5.2038Expires
Marketing license
IS authorization number:
EU/1/23/1736Date:
12.6.2023
Foreign authorization number:
EU/1/23/1736Date:
26.5.2023
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis, IN 46285 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2964258
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 18.07.2025